BioSig Technologies says it has entered into three new evaluation agreements for its PURE EP System

BioSig Technologies, Inc. (NASDAQ:BSGM) said it has entered into three new evaluation agreements for the PURE EP System, its novel electrophysiology (EP) signal acquisition and analysis technology.

The group said new clinical sites due to receive BioSig’s PURE EP System include New York-Presbyterian/Weill Cornell Medical Center, Michigan Medicine–University Hospital – two centers that account for two of the largest EP programs in the country - and Houston Methodist Hospital.

More than 500 patient cases have been conducted using the PURE EP System by 34 physicians in seven clinical sites to date, it added.

READ: BioSig Technologies collaborates with Mayo Clinic on artificial intelligence R&D program for its PURE EP system

New installations of the PURE EP System will now follow a shorter assessment cycle of 90 days based on favorable data from installation evaluations in 2020. As part of its evaluation agreements, the company’s clinical team provides on-site training and assists with data collection and interpretation, and workflow customization to optimize the user experience for every physician and EP lab staff member.

“Since initiating our first clinical study in November 2019, our team has acquired a wealth of knowledge about the capabilities of the PURE EP System in a broad range of clinical cases,” commented Kenneth L. Londoner, chairman, and CEO of BioSig Technologies in a statement.

“Our experience in 2020 has provided the Company meaningful strategic information that gives us confidence in accelerating our rollout and reducing the clinical evaluation period to 90 days or less, beginning with these three major hospitals. With the recent decline of COVID-19 cases reported and the resulting decline in hospitalization rates in the past several weeks, our Company is poised to expand near-term activity on our targeted commercial plans for 2021.”

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals.

The company’s first product, PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Contact the author at [email protected]

Story by ProactiveInvestors